Table 1 Biological data. Scoring of active compounds from SAR screening
Post-emergence | Pre-emergence | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Compound | AMARE | LOLPE | STEME | DIGSA | Symptom | AMARE | LOLPE | STEME | DIGSA | Symptom |
(+)-1 | 90 | 60 | NT | 90 | ST/DS | 80 | 90 | NT | 100 | ST/DS |
(±)-1 | 40 | 0 | 50 | 60 | NC/ST | 70 | 40 | 70 | 80 | NC/ST |
(±)-2 | 0 | 0 | 0 | 0 | — | 0 | 0 | 0 | 0 | — |
(±)-3 | 0 | 0 | 0 | 0 | — | 0 | 0 | 0 | 0 | — |
16 | 0 | 0 | 0 | 0 | ST | 0 | 0 | 50 | 0 | ST |
21 | 0 | 0 | 70 | 20 | NC/ST | 0 | 0 | 0 | 0 | NC/ST |
32* | 0 | 0 | 0 | 0 | ST | 50 | 0 | 80 | 0 | ST |
35 | 0 | 0 | 0 | 0 | ST | 20 | 0 | 50 | 50 | ST |
36* | 50 | 40 | 0 | 60 | ST | 40 | 30 | 50 | 50 | ST |
38a* | 70 | 70 | 70 | 80 | NC/ST | 80 | 60 | 80 | 80 | NC/ST |
41a | 30 | 20 | 30 | 60 | GI/ST | 0 | 20 | 80 | 0 | GI/ST |
43a* | 30 | 10 | 0 | 50 | GI/ST | 30 | 60 | 40 | 80 | GI/ST |
45a | 30 | 20 | 10 | 100 | NC/ST | 20 | 20 | 20 | 40 | NC/ST |
39b* | 20 | 0 | 40 | 0 | ST | 30 | 40 | 70 | 0 | ST |
